Spirocercosis

Spirocercosis is a parasitic disease of dogs and wild canids caused by the nematode Spirocerca lupi. The adult worms typically form nodular masses in the esophagus, stomach, and aorta, leading to a spectrum of clinical signs including regurgitation, dysphagia, vomiting, weight loss, and occasionally fatal hemorrhage or neoplasia. The disease is most prevalent in tropical and subtropical regions, with a complex life cycle involving coprophagous beetles as intermediate hosts and various paratenic hosts. Spirocercosis is a significant cause of morbidity and mortality in endemic areas, and its clinical presentation can mimic esophageal neoplasia, making accurate diagnosis and management crucial.

The causative agent is Spirocerca lupi, a spirurid nematode. Adult worms are reddish, coiled, and measure up to 8 cm in length. The life cycle involves eggs passed in feces, which are ingested by coprophagous beetles (intermediate hosts). Larvae develop in the beetle and become infective. Dogs acquire infection by ingesting infected beetles or paratenic hosts (e.g., birds, rodents, lizards) that have consumed beetles. Larvae penetrate the gastric wall and migrate through the arterial wall, typically to the thoracic aorta, where they develop. Eventually, they migrate to the esophagus, where they induce granulomatous nodules. The prepatent period is approximately 5-6 months. Virulence factors include the nematode's ability to induce host tissue proliferation and its secretion of immunomodulatory molecules that facilitate immune evasion.

Spirocercosis is endemic in tropical and subtropical regions worldwide, including parts of Africa, Asia, the Middle East, and southern Europe. In the United States, it is reported in the southeastern states, particularly in the Gulf Coast region. Dogs of any breed, age, or sex are susceptible, but young to middle-aged dogs (1-3 years) are more commonly affected. Outdoor dogs with access to intermediate hosts are at higher risk. The prevalence can be high in certain regions; for example, in Israel, up to 30% of dogs in some areas may be infected. The disease is more common in rural areas where beetles and paratenic hosts are abundant. Seasonal variation may occur, with higher transmission during warm months when beetle activity peaks.

After ingestion, infective larvae penetrate the gastric mucosa and migrate to the aorta, where they reside in the arterial wall for several months. This migration causes arteritis, aneurysm formation, and sometimes aortic rupture. Larvae then migrate to the esophagus, where they stimulate a granulomatous inflammatory response, forming nodules that contain adult worms. These nodules can become large and may undergo neoplastic transformation, most commonly to esophageal sarcoma (osteosarcoma, fibrosarcoma). The mechanism of neoplasia is not fully understood but may involve chronic inflammation and growth factor secretion by the parasite. Esophageal nodules can cause mechanical obstruction, leading to regurgitation and dysphagia. Aortic lesions can lead to thromboembolism or rupture, causing acute death. In some cases, aberrant migration can affect other organs, including the lungs, kidneys, and spinal cord.

Intrinsic factors include age (young dogs more likely to be infected), immune status (immunosuppressed dogs may have more severe disease), and genetic susceptibility (certain breeds may be overrepresented, though not well-documented). Extrinsic factors include geographic location (endemic areas), lifestyle (outdoor access, hunting), and management practices (poor sanitation, lack of preventive deworming). Concurrent infections or malnutrition may increase susceptibility. The presence of paratenic hosts in the environment also increases exposure risk.

Clinical signs vary depending on the stage and severity of infection. In the early migratory phase, signs may be absent or nonspecific. As esophageal nodules develop, common signs include regurgitation, dysphagia, vomiting, hypersalivation, and weight loss. Dogs may also exhibit coughing, respiratory distress, and fever. Aortic involvement can lead to acute collapse or sudden death due to rupture. In chronic cases, signs of esophageal neoplasia may develop, including progressive dysphagia, cachexia, and respiratory signs. Some dogs may have palpable esophageal masses on physical examination. Neurological signs can occur if aberrant migration affects the spinal cord, leading to paresis or paralysis.

Differential diagnoses for spirocercosis include: 1) Esophageal neoplasia (e.g., squamous cell carcinoma, leiomyosarcoma) - distinguished by histopathology and imaging (CT, endoscopy with biopsy). 2) Esophageal foreign body - identified by radiography or endoscopy. 3) Esophageal stricture - often due to previous trauma or inflammation, diagnosed by barium swallow or endoscopy. 4) Megaesophagus - generalized esophageal dilation, often idiopathic or secondary to myasthenia gravis, diagnosed by thoracic radiography and acetylcholine receptor antibody testing. 5) Gastroesophageal reflux disease - causes esophagitis, diagnosed by endoscopy and response to antacids. 6) Hiatal hernia - intermittent regurgitation, confirmed by thoracic radiography or fluoroscopy. 7) Granulomatous esophagitis (e.g., fungal) - biopsy and culture. 8) Vascular ring anomaly - congenital, seen in young dogs, diagnosed by barium esophagram. 9) Pulmonary disease (e.g., aspiration pneumonia) - may cause coughing and regurgitation, but primary esophageal signs are absent. 10) Chronic gastritis or gastric outflow obstruction - may cause vomiting, but regurgitation is less common.

The diagnostic approach begins with a thorough history and physical examination, with attention to regurgitation and weight loss. Thoracic radiographs may reveal an esophageal mass, megaesophagus, or aortic abnormalities. Fecal examination using flotation or sedimentation can detect eggs, but sensitivity is low (approximately 30-50%). Esophagoscopy is the gold standard for visualization of nodules and collection of biopsy samples for histopathology and identification of adult worms. Advanced imaging, such as CT or MRI, is useful for assessing the extent of lesions and detecting aortic involvement. In endemic areas, a positive fecal test or characteristic imaging findings may be sufficient for presumptive diagnosis. Definitive diagnosis requires identification of eggs, larvae, or adult worms, or histopathological confirmation of the parasite in tissue.

Hematology may show mild anemia, eosinophilia (in some cases), and leukocytosis. Serum biochemistry may reveal hypoalbuminemia, elevated globulins (due to chronic inflammation), and elevated liver enzymes if hepatic migration occurs. Urinalysis is usually unremarkable. Specific biomarkers such as C-reactive protein (CRP) may be elevated. Serological tests (ELISA) for antibody detection are available but not widely used. PCR-based assays on fecal samples or tissue biopsies can confirm infection. In cases of aortic rupture, acute anemia and shock may be evident. Neoplastic transformation may be associated with elevated alkaline phosphatase and calcium levels if osteosarcoma is present.

Thoracic radiographs may show a soft tissue mass in the caudal esophagus, often with a gas-filled lumen. Aortic abnormalities, such as aneurysmal dilation or mineralization, may be visible. Barium esophagram can delineate the mass and assess obstruction. Ultrasonography is less useful for esophageal lesions but can evaluate the aorta and detect nodules. Computed tomography (CT) provides detailed cross-sectional imaging of the esophagus, aorta, and surrounding structures, and is excellent for surgical planning. Magnetic resonance imaging (MRI) is superior for soft tissue contrast and can help differentiate benign from malignant lesions. Endoscopy is the most direct imaging modality, allowing visualization of nodules, retrieval of worms, and biopsy. Fluoroscopy can assess esophageal motility and obstruction.

Fine needle aspiration of esophageal nodules may yield inflammatory cells, eosinophils, and occasionally parasitic larvae or eggs. Cytology is often nondiagnostic. Histopathology of biopsy samples reveals granulomatous inflammation with fibrosis, and the presence of adult worms or larvae within the tissue. In neoplastic transformation, features of sarcoma (e.g., osteosarcoma, fibrosarcoma) are seen, with malignant spindle cells and osteoid or collagen production. Special stains (e.g., trichrome) may highlight collagen. Immunohistochemistry can help differentiate tumor types.

Treatment of spirocercosis involves anthelmintic therapy and supportive care. The drug of choice is doramectin (0.4 mg/kg SC, repeated every 2 weeks for 3-4 treatments) or ivermectin (0.2 mg/kg SC, repeated every 2 weeks for 3-4 treatments). These macrocyclic lactones are effective against adult worms. Alternatively, milbemycin oxime (0.5-1.0 mg/kg PO, every 2 weeks for 3-4 treatments) can be used. Surgical removal of esophageal nodules may be necessary for large, obstructive, or neoplastic masses. Supportive care includes nutritional support (e.g., feeding tubes), antiemetics (e.g., maropitant 1 mg/kg IV or PO q24h), and management of complications such as aspiration pneumonia (e.g., amoxicillin-clavulanate 20 mg/kg PO q12h). In cases of aortic aneurysm, surgical intervention may be considered but is high-risk. Analgesics (e.g., tramadol 2-5 mg/kg PO q8-12h) may be needed for pain. Prognosis is guarded if neoplasia is present.

The prognosis for spirocercosis is variable. With early diagnosis and appropriate anthelmintic therapy, many dogs recover fully. However, the presence of esophageal neoplasia significantly worsens the prognosis, with a median survival time of less than 6 months despite treatment. Aortic rupture is often fatal. Negative prognostic indicators include neoplastic transformation, severe clinical signs, and delayed treatment. Response to treatment is monitored by resolution of clinical signs and reduction in nodule size on imaging. Recurrence is possible if reinfection occurs.

After treatment, dogs should be re-examined at 2-week intervals during anthelmintic therapy. Fecal examinations should be repeated monthly for 3 months to confirm clearance of infection. Thoracic radiographs or ultrasound should be repeated at 3 and 6 months to assess nodule regression. If nodules persist or enlarge, biopsy is recommended to rule out neoplasia. Long-term monitoring every 6-12 months is advised for dogs in endemic areas. Preventive measures include regular deworming with macrocyclic lactones (e.g., ivermectin 6 mcg/kg PO monthly) and reducing exposure to intermediate hosts.

Pearls: 1) In endemic areas, spirocercosis should be a top differential for regurgitation and esophageal mass. 2) Fecal examination is often negative; endoscopy is the most reliable diagnostic tool. 3) Doramectin is highly effective and well-tolerated. 4) Aortic lesions may be asymptomatic but can be life-threatening. Pitfalls: 1) Misdiagnosing spirocercosis as esophageal neoplasia without biopsy. 2) Using anthelmintics at incorrect dosages or intervals, leading to treatment failure. 3) Overlooking the possibility of aortic rupture in dogs with acute collapse. 4) Failing to monitor for neoplastic transformation in chronic cases.

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: 1) Doramectin: 0.4 mg/kg SC, repeated every 14 days for 3-4 treatments. 2) Ivermectin: 0.2 mg/kg SC, repeated every 14 days for 3-4 treatments. 3) Milbemycin oxime: 0.5-1.0 mg/kg PO, every 14 days for 3-4 treatments. 4) For prevention in endemic areas: Ivermectin 6 mcg/kg PO monthly, or milbemycin oxime 0.5 mg/kg PO monthly. 5) Supportive care: Maropitant 1 mg/kg IV or PO q24h for vomiting; omeprazole 1 mg/kg PO q12h for esophagitis; amoxicillin-clavulanate 20 mg/kg PO q12h for aspiration pneumonia. 6) Analgesics: Tramadol 2-5 mg/kg PO q8-12h. 7) In cases of neoplastic transformation, chemotherapy (e.g., doxorubicin 30 mg/m² IV q3 weeks) may be considered, but efficacy is limited. Dosages should be adjusted for renal or hepatic impairment, and drug interactions should be considered (e.g., ivermectin with other P-glycoprotein substrates).

Key studies include: 1) A study by van der Merwe et al. (2008) demonstrated that doramectin is effective in treating spirocercosis, with a cure rate of 90% after 3-4 doses. 2) A retrospective study by Ranen et al. (2004) reported that esophageal sarcoma develops in approximately 25% of chronic cases, with a poor prognosis. 3) ACVIM consensus guidelines on parasitic diseases recommend macrocyclic lactones as first-line therapy. 4) A study by Mazaki-Tovi et al. (2002) evaluated the use of milbemycin oxime and found it effective. 5) Research by Dvir et al. (2001) described the clinical and pathological features of spirocercosis in dogs. 6) A recent study by Kirberger et al. (2013) used CT to characterize esophageal nodules and differentiate benign from malignant lesions. These studies support the current diagnostic and therapeutic approach.